INC Research ($INCR) added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient. The FDA requires so-called QT testing for all novel cardio drugs, demanding data on how each agent affects the time between two intervals in the heart's electrical cycle. Such tests are often done separate from Phase I safety studies, adding a costly and time-consuming step to early development. INC, partnering with a company called iCardiac, now offers an integrated QT test that gathers the necessary data during standard Phase I trials. More